Literature DB >> 35898245

Formulary Drug Review: Belumosudil.

Terri L Levien1, Danial E Baker1.   

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433.
© The Author(s) 2021.

Entities:  

Year:  2021        PMID： 35898245      PMCID： PMC9310299          DOI： 10.1177/00185787211061381

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  10 in total

Review 1.  Cytokine mediators of chronic graft-versus-host disease.

Authors:  Kelli Pa MacDonald; Bruce R Blazar; Geoffrey R Hill
Journal:  J Clin Invest       Date:  2017-06-30       Impact factor: 14.808

2.  The selective ROCK2 inhibitor KD025 reduces IL-17 secretion in human peripheral blood mononuclear cells independent of IL-1 and IL-6.

Authors:  Isak W Tengesdal; David Kitzenberg; Suzhao Li; Melanie S Nyuydzefe; Wei Chen; Jonathan M Weiss; Jingya Zhang; Samuel D Waksal; Alexandra Zanin-Zhorov; Charles A Dinarello
Journal:  Eur J Immunol       Date:  2018-09-21       Impact factor: 5.532

Review 3.  Evolving Therapeutic Options for Chronic Graft-versus-Host Disease.

Authors:  Rebecca M Gonzalez; Joseph Pidala
Journal:  Pharmacotherapy       Date:  2020-06-15       Impact factor: 4.705

4.  Targeting the RhoA-ROCK pathway to reverse T-cell dysfunction in SLE.

Authors:  Cristina Rozo; Yurii Chinenov; Reena Khianey Maharaj; Sanjay Gupta; Laura Leuenberger; Kyriakos A Kirou; Vivian P Bykerk; Susan M Goodman; Jane E Salmon; Alessandra B Pernis
Journal:  Ann Rheum Dis       Date:  2016-11-09       Impact factor: 19.103

5.  Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism.

Authors:  Ryan Flynn; Katelyn Paz; Jing Du; Dawn K Reichenbach; Patricia A Taylor; Angela Panoskaltsis-Mortari; Ante Vulic; Leo Luznik; Kelli K P MacDonald; Geoffrey R Hill; Melanie S Nyuydzefe; Jonathan M Weiss; Wei Chen; Alissa Trzeciak; Jon S Serody; Ethan G Aguilar; William J Murphy; Ivan Maillard; David Munn; John Koreth; Corey S Cutler; Joseph H Antin; Jerome Ritz; Samuel D Waksal; Alexandra Zanin-Zhorov; Bruce R Blazar
Journal:  Blood       Date:  2016-03-16       Impact factor: 22.113

6.  Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism.

Authors:  Alexandra Zanin-Zhorov; Jonathan M Weiss; Melanie S Nyuydzefe; Wei Chen; Jose U Scher; Rigen Mo; David Depoil; Nishta Rao; Ben Liu; Jianlu Wei; Sarah Lucas; Matthew Koslow; Maria Roche; Olivier Schueller; Sara Weiss; Masha V Poyurovsky; James Tonra; Keli L Hippen; Michael L Dustin; Bruce R Blazar; Chuan-ju Liu; Samuel D Waksal
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-10       Impact factor: 11.205

7.  Cutting Edge: Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis Vulgaris and Normalizes Skin Pathology via Concurrent Regulation of IL-17 and IL-10.

Authors:  Alexandra Zanin-Zhorov; Jonathan M Weiss; Alissa Trzeciak; Wei Chen; Jingya Zhang; Melanie S Nyuydzefe; Carmen Arencibia; Seetharam Polimera; Olivier Schueller; Judilyn Fuentes-Duculan; Kathleen M Bonifacio; Norma Kunjravia; Inna Cueto; Jennifer Soung; Roy M Fleischmann; Alan Kivitz; Mark Lebwohl; Margarita Nunez; Johnnie Woodson; Shondra L Smith; Robert F West; Mark Berger; James G Krueger; John L Ryan; Samuel D Waksal
Journal:  J Immunol       Date:  2017-04-07       Impact factor: 5.422

8.  ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease.

Authors:  Madan Jagasia; Aleksandr Lazaryan; Carlos R Bachier; Amandeep Salhotra; Daniel J Weisdorf; Behyar Zoghi; James Essell; Laurie Green; Olivier Schueller; Jeegar Patel; Alexandra Zanin-Zhorov; Jonathan M Weiss; Zhongming Yang; David Eiznhamer; Sanjay K Aggarwal; Bruce R Blazar; Stephanie J Lee
Journal:  J Clin Oncol       Date:  2021-04-20       Impact factor: 50.717

9.  KD025 (SLx-2119) suppresses adipogenesis at intermediate stage in human adipose-derived stem cells.

Authors:  Duy Trong Vien Diep; Khue Ha Minh Duong; Hojung Choi; Hee-Sook Jun; Kwang-Hoon Chun
Journal:  Adipocyte       Date:  2019-03-23       Impact factor: 4.534

10.  Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study.

Authors:  Corey Cutler; Stephanie J Lee; Sally Arai; Marcello Rotta; Behyar Zoghi; Aleksandr Lazaryan; Aravind Ramakrishnan; Zachariah DeFilipp; Amandeep Salhotra; Wanxing Chai-Ho; Rohtesh Mehta; Trent Wang; Mukta Arora; Iskra Pusic; Ayman Saad; Nirav N Shah; Sunil Abhyankar; Carlos Bachier; John Galvin; Annie Im; Amelia Langston; Jane Liesveld; Mark Juckett; Aaron Logan; Levanto Schachter; Asif Alavi; Dianna Howard; Harlan W Waksal; John Ryan; David Eiznhamer; Sanjay K Aggarwal; Jonathan Ieyoub; Olivier Schueller; Laurie Green; Zhongming Yang; Heidi Krenz; Madan Jagasia; Bruce R Blazar; Steven Pavletic
Journal:  Blood       Date:  2021-12-02       Impact factor: 25.476
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.